Literature DB >> 9016899

Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats.

B D Cowley1, J C Rupp, M J Muessel, V H Gattone.   

Abstract

Human autosomal dominant polycystic kidney disease (ADPKD) is a common inherited disease and displays a gender dimorphism in renal disease progression. Han:SPRD-Cy rats manifest a form of ADPKD that is similar in many respects to that seen in humans. In Han:SPRD rats, male Cy/+ rats have more prominent renal changes and develop renal failure at an early age, whereas female Cy/+ rats exhibit less severe renal cystic change and have normal renal function until advanced age. To determine whether the male gonadal hormone, testosterone, contributes to this gender dimorphism, males were sham operated or castrated; some castrated rats were repleted with 5alpha-dihydrotestosterone. Female rats were sham operated or ovariectomized before sham operation or testosterone treatment. All treatments started at 4 weeks of age and ended at 10 weeks of age. Renal enlargement, cystic change, and renal function were assessed. In the males, castration reduced renal enlargement and cystic change; testosterone treatment abrogated these effects. Neither of these manipulations affected azotemia in male Cy/+ rats. In the females, testosterone was renotropic for both normal and cystic kidneys. In the Cy/+ females, testosterone treatment caused azotemia and an increase in the severity of the PKD. Ovariectomy blunted the effect of testosterone on cystic kidney enlargement. Testosterone treatment did not completely erase the gender-associated differences in azotemia in the Cy/+ rat. These data confirm the renotropic effects of testosterone and indicate that testosterone influences the progression of renal cystic change in male and female rats with ADPKD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9016899     DOI: 10.1016/s0272-6386(97)90039-1

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  27 in total

1.  2-Hydroxyestradiol slows progression of experimental polycystic kidney disease.

Authors:  Sharon Anderson; Terry T Oyama; Jessie N Lindsley; William E Schutzer; Douglas R Beard; Vincent H Gattone; Radko Komers
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-07

2.  Hypoxia-inducible factor-1α (HIF-1α) and autophagy in polycystic kidney disease (PKD).

Authors:  Franck Belibi; Iram Zafar; Kameswaran Ravichandran; Anamarija Bauer Segvic; Alkesh Jani; Danica Galesic Ljubanovic; Charles L Edelstein
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

3.  Calcimimetic inhibits late-stage cyst growth in ADPKD.

Authors:  Vincent H Gattone; Neal X Chen; Rachel M Sinders; Mark F Seifert; Danxia Duan; David Martin; Charles Henley; Sharon M Moe
Journal:  J Am Soc Nephrol       Date:  2009-05-07       Impact factor: 10.121

4.  A rat model of chronic kidney disease-mineral bone disorder.

Authors:  Sharon M Moe; Neal X Chen; Mark F Seifert; Rachel M Sinders; Dana Duan; Xianming Chen; Yun Liang; J Scott Radcliff; Kenneth E White; Vincent H Gattone
Journal:  Kidney Int       Date:  2008-09-17       Impact factor: 10.612

5.  An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.

Authors:  Kameswaran Ravichandran; Iram Zafar; Zhibin He; R Brian Doctor; Radu Moldovan; Adam E Mullick; Charles L Edelstein
Journal:  Hum Mol Genet       Date:  2014-05-08       Impact factor: 6.150

6.  Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease.

Authors:  Yunxia Tao; Jun Kim; Sarah Faubel; Joe C Wu; Sandor A Falk; Robert W Schrier; Charles L Edelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-29       Impact factor: 11.205

7.  An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.

Authors:  Kameswaran Ravichandran; Iram Zafar; Abdullah Ozkok; Charles L Edelstein
Journal:  Nephrol Dial Transplant       Date:  2014-09-19       Impact factor: 5.992

Review 8.  The renal effects of ALK inhibitors.

Authors:  Hassan Izzedine; Rania Kheder El-Fekih; Mark A Perazella
Journal:  Invest New Drugs       Date:  2016-07-29       Impact factor: 3.850

9.  Cystic renal disease in the domestic ferret.

Authors:  Courtnye N Jackson; Arlin B Rogers; Kirk J Maurer; Jennifer L S Lofgren; James G Fox; Robert P Marini
Journal:  Comp Med       Date:  2008-04       Impact factor: 0.982

10.  Human and murine kidneys show gender- and species-specific gene expression differences in response to injury.

Authors:  Han Si; Ramandeep S Banga; Pinelopi Kapitsinou; Manjunath Ramaiah; Janis Lawrence; Ganesh Kambhampati; Antje Gruenwald; Erwin Bottinger; Daniel Glicklich; Vivian Tellis; Stuart Greenstein; David B Thomas; James Pullman; Melissa Fazzari; Katalin Susztak
Journal:  PLoS One       Date:  2009-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.